Overview

Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study was to evaluate the safety and efficacy of afamelanotide in patients suffering from polymorphic light eruption (PLE).
Phase:
Phase 3
Details
Lead Sponsor:
Clinuvel Pharmaceuticals Limited
Treatments:
Afamelanotide